J9061 HCPCS code: Injection, amivantamab-vmjw, 2 mg
J9061 is the HCPCS Level II code for injection, amivantamab-vmjw, 2 mg. In 2024 Medicare paid an average of $15.63 per service for J9061 across 1,042,166 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1050 per day on DME suppliers. Medicare volume rose 175% from 2022 to 2024 (379,436 to 1,042,166 services). In 2024, about 537 clinicians billed Medicare for J9061 for 278 beneficiaries; California, Texas, Florida accounted for 77% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2022-01-01 |
| Last action effective | 2022-01-01 |
Who bills J9061 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 537 |
| Medicare beneficiaries | 278 |
| States with claims | 5 |
| Share of services in top 3 states (California, Texas, Florida) | 77% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9061, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 379,436 | 79 | $17.29 | $13.80 |
| 2023 | 469,709 | 101 | $18.98 | $15.13 |
| 2024 | 1,042,166 | 278 | $19.58 | $15.63 |
States with the most J9061 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 162,753 | $15.67 |
| Texas | 118,301 | $15.35 |
| Florida | 95,201 | $15.36 |
| Illinois | 85,400 | $16.00 |
| Maryland | 27,475 | $12.34 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 1050 | Prescribing Information |
| outpatient hospital claims | 1050 | Prescribing Information |
| practitioner claims | 1050 | Prescribing Information |
What changed for J9061
- 2022-01-01: J9061 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9061?
J9061 is the HCPCS Level II code for injection, amivantamab-vmjw, 2 mg. Short descriptor: "Inj, amivantamab-vmjw".
How much does Medicare pay for J9061?
In 2024, the average Medicare payment was $15.63 per service (average allowed $19.58).
Does Medicare cover J9061?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9061 can be billed per day?
1050 on DME suppliers; 1050 on outpatient hospital claims; 1050 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9061
- Watch J9061 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9061
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.